NCT02303327View on ClinicalTrials.gov

Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2029

Conditions
Prostate Cancer
Interventions
RADIATION

EBRT + HDR brachytherapy boost

Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.

RADIATION

Hypofractionated Dose Escalation Radiotherapy

Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.

DRUG

Androgen deprivation therapy

28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)

Trial Locations (12)

A1B 3V6

Eastern Health, St. John's

N6C 2R5

Lawson Health Research Institute, London

N8W2X3

Windsor Regional Hospital, Windsor

J8P 7H2

Centre Hospitalier des Vallées de l'Outaouais, Hôpital de Gatineau, Gatineau

H2L 4M1

CHUM Notre-Dame, Montreal

H3G 1A4

Montréal General Hospital, Montreal

H3T 1E2

Jewish General Hospital, McGill University, Montreal

G1R 2J6

CHUQ, L'Hôtel-Dieu de Québec, Québec

G5L 5T1

Centre de santé Rimouski-Neigette, Rimouski

J1H 5N4

CHUS - Hôpital Fleurimont, Sherbrooke

G8Z 3R9

Centre Hospitalier régional de Trois-Rivières, Trois-Rivières

S4T 7T1

Allan Blair Cancer Centre, Regina

All Listed Sponsors
lead

Sir Mortimer B. Davis - Jewish General Hospital

OTHER